Skip to main content

PerkinElmer, Inc. (PKI)

NYSE: PKI · IEX Real-Time Price · USD
183.17 3.18 (1.77%)
Dec 3, 2021 4:05 PM EST - Market closed
Market Cap23.78B
Revenue (ttm)5.06B
Net Income (ttm)1.13B
Shares Out129.81M
EPS (ttm)10.02
PE Ratio18.27
Forward PE25.45
Dividend$0.28 (0.15%)
Ex-Dividend DateJan 20, 2022
Volume1,157,084
Open181.31
Previous Close179.99
Day's Range176.73 - 184.40
52-Week Range119.95 - 192.00
Beta1.06
AnalystsBuy
Price Target188.82 (+3.1%)
Earnings DateNov 2, 2021

About PKI

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, ...

IndustryLife Sciences Tools & Services
Founded1937
CEOPrahlad Singh
Employees15,000
Stock ExchangeNYSE
Ticker SymbolPKI
Full Company Profile

Financial Performance

In 2020, PerkinElmer's revenue was $3.78 billion, an increase of 31.18% compared to the previous year's $2.88 billion. Earnings were $727.89 million, an increase of 219.87%.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for PerkinElmer stock is "Buy." The 12-month stock price forecast is 188.82, which is an increase of 3.08% from the latest price.

Price Target
$188.82
(3.08% upside)
Analyst Consensus: Buy

News

PerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue?

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

1 day ago - Zacks Investment Research

PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are no...

4 days ago - Business Wire

5 GARP Stocks That Look Like Good Bets to Me

Barring a reversal in the last few weeks of this year, growth stocks will beat value stocks in 2021 for the fifth time in a row.

1 week ago - GuruFocus

PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its PKeye™ Workflow Monitor, a cloud-based platform enabl...

1 week ago - Business Wire

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

2 weeks ago - Zacks Investment Research

PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Evercore ISI 4th Annua...

2 weeks ago - Business Wire

PerkinElmer to Present at 2021 Stifel Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual 2021 Stifel He...

4 weeks ago - Business Wire

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.

1 month ago - Zacks Investment Research

PerkinElmer Q3 Earnings, FY21 Guidance Beat Wall Street Expectations

PerkinElmer Inc's (NYSE: PKI) Q3 revenues increased 21% Y/Y (12% organic) to $1.17 billion, beating the consensus of $1.04 billion. Diagnostics segment posted $654 million in revenues, +21% (13% organic).

1 month ago - Benzinga

PerkinElmer (PKI) Beats Q3 Earnings and Revenue Estimates

PerkinElmer (PKI) delivered earnings and revenue surprises of 35.88% and 16.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

PerkinElmer Announces Financial Results for the Third Quarter of 2021

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 3, 202...

1 month ago - Business Wire

Should You Buy PerkinElmer (PKI) Ahead of Earnings?

PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

PerkinElmer Releases 2021 Corporate Social Responsibility Report

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes t...

1 month ago - Business Wire

PerkinElmer Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 27, 2021. This dividend is paya...

1 month ago - Business Wire

PerkinElmer (PKI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.

1 month ago - Zacks Investment Research

PerkinElmer and International Society for Neonatal Screening Host Virtual Summit to Discuss Implementation of India's...

DELHI, India--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, joined forces with the International Society for Neonatal Screening (ISNS) to host the In...

1 month ago - Business Wire

PerkinElmer Signals Research Suite Platform Integrates Scientific Data Silos and Enhances Collaboration for R&D Teams

WALTHAM, Mass.--(BUSINESS WIRE)--Signals Research™ Suite provides secure, SaaS platform helping pharma and industrial R&D teams make more efficient & effective data-driven decisions.

1 month ago - Business Wire

PerkinElmer (PKI) Sees Hammer Chart Pattern: Time to Buy?

PerkinElmer (PKI) has been struggling lately, but the selling pressure may be coming to an end soon.

1 month ago - Zacks Investment Research

Which Stocks Are More Attractive Than eBay's Stock?

We believe that there are other stocks that are currently better valued than eBay's stock. EBAY's current price-to-operating income ratio (P/EBIT) of 16.7x is higher than levels of 13.3x for PerkinElmer...

Other symbols:AGCOBIODISHLEN
1 month ago - Forbes

PKI or MTD: Which Is the Better Value Stock Right Now?

PKI vs. MTD: Which Stock Is the Better Value Option?

Other symbols:MTD
1 month ago - Zacks Investment Research

Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

Looking for Earnings Beat? Play These 5 Stocks

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Other symbols:BYDCRIPZZAULTA
1 month ago - Zacks Investment Research

PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling

PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.

1 month ago - Zacks Investment Research

PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer and Honeycomb Biotechnologies, Inc., have launched the first of its kind HIVE scRNAseq Solution for single-cell isolation and analysis.

1 month ago - Business Wire